[2] [2] Shi Y, Tian M, Zhao X, et al. -Ketoglutarate promotes cardiomyocyte proliferation and heart regeneration after myocardial infarction[J]. Nat Cardiovasc Res, 2024, 3(9): 1083-1097.

[3] [3] Puente BN, Kimura W, Muralidhar SA, et al. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response[J]. Cell, 2014, 157(3): 565-579.

[4] [4] Zhang B, Zhang Y, Zhang K, et al. The coronary angiography-derived index of microcirculatory resistance predicts perioperative myocardial injury in stable coronary artery disease patients undergoing PCI[J]. Heliyon, 2024, 10(15): e35240.

[5] [5] Huang GN, Thatcher JE, McAnally J, et al. C/EBP transcription factors mediate epicardial activation during heart development and injury[J]. Science, 2012, 338(6114): 1599-1603.

[7] [7] Feng J, Li Y, Li Y, et al. Versican promotes cardiomyocyte proliferation and cardiac repair[J]. Circulation, 2024, 149(13): 1004-1015.

[8] [8] Padula SL, Velayutham N, Yutzey KE. Transcriptional regulation of postnatal cardiomyocyte maturation and regeneration[J]. Int J Mol Sci, 2021, 22(6): 3288.

[9] [9] Zhu C, Yuan T, Krishnan J. Targeting cardiomyocyte cell cycle regulation in heart failure[J]. Basic Res Cardiol, 2024, 119(3): 349-369.

[10] [10] Cutie S, Huang GN. Vertebrate cardiac regeneration: evolutionary and developmental perspectives[J]. Cell Regen, 2021, 10(1): 6.

[11] [11] Li Y, Feng J, Song S, et al. gp130 controls cardiomyocyte proliferation and heart regeneration[J]. Circulation, 2020, 142(10): 967-982.

[12] [12] Santos F, Correia M, Nbrega-Pereira S, et al. Age-related pathways in cardiac regeneration: a role for lncRNAs?[J]. Front Physiol, 2021, 11: 583191.

[13] [13] Yin HM, Burns CG, Burns CE. Innate mechanisms of heart regeneration[J]. Cold Spring Harb Perspect Biol, 2021, 13(11): a040766.

[14] [14] Daskalopoulos EP, Blankesteijn WM. Effect of interventions in WNT signaling on healing of cardiac injury: a systematic review[J]. Cells, 2021, 10(2): 207.

[15] [15] Liu X, Pu W, He L, et al. Cell proliferation fate mapping reveals regional cardiomyocyte cell-cycle activity in subendocardial muscle of left ventricle[J]. Nat Commun, 2021, 12(1): 5784.

[16] [16] Heallen TR, Kadow ZA, Wang J, et al. Determinants of cardiac growth and size[J]. Cold Spring Harb Perspect Biol, 2020, 12(3): a037150.

[17] [17] Wang Y, Wei J, Zhang P, et al. Neuregulin-1, a potential therapeutic target for cardiac repair[J]. Front Pharmacol, 2022, 13: 945206.

[18] [18] Li D, Sun J, Zhong TP. Wnt signaling in heart development and regeneration[J]. Curr Cardiol Rep, 2022, 24(10): 1425-1438.

[19] [19] Peng X, Fan S, Tan J, et al. Wnt2bb induces cardiomyocyte proliferation in zebrafish hearts via the jnk1/c-Jun/creb1 pathway[J]. Front Cell Dev Biol, 2020, 8: 323.

[20] [20] Csbnyeiov M, Beerov N, Klein M, et al. Cell-based and selected cell-free therapies for myocardial in-farction: how do they compare to the current treatment options?[J]. Int J Mol Sci, 2022, 23(18): 10314.

[21] [21] Sugiura T, Shahannaz DC, Ferrell BE. Current status of cardiac regenerative therapy using induced pluripotent stem cells[J]. Int J Mol Sci, 2024, 25(11): 5772.

[22] [22] Arjmand B, Abedi M, Arabi M, et al. Regenerative medicine for the treatment of ischemic heart disease; status and future perspectives[J]. Front Cell Dev Biol, 2021, 9: 704903.

[23] [23] Tong J, Ding J, Shen X, et al. Mesenchymal stem cell transplantation enhancement in myocardial infarction rat model under ultrasound combined with nitric oxide microbubbles[J]. PLoS One, 2013, 8(11): e80186.

[24] [24] Wu R, Ma F, Tosevska A, et al. Cardiac fibroblast proliferation rates and collagen expression mature early and are unaltered with advancing age[J]. JCI Insight, 2020, 5(24): e140628.

[25] [25] Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to my-oblasts[J]. Cell, 1987, 51(6): 987-1000.

[26] [26] Murry CE, Kay MA, Bartosek T, et al. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD[J]. J Clin Invest, 1996, 98(10): 2209-2217.

[27] [27] Ieda M. Direct reprogramming into desired cell types by defined factors[J]. Keio J Med, 2013, 62(3): 74-82.

[28] [28] Rurik JG, Tombcz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury[J]. Science, 2022, 375(6576): 91-96.

[29] [29] Werner JH, Rosenberg JH, Um JY, et al. Molecular discoveries and treatment strategies by direct repro-gramming in cardiac regeneration[J]. Transl Res, 2019, 203: 73-87.

[30] [30] Xie N, Robinson K, Sundquist T, et al. In vivo PSC differentiation as a platform to identify factors for im-proving the engraftability of cultured muscle stem cells[J]. Front Cell Dev Biol, 2024, 12: 1362671.

[31] [31] Santos F, Correia M, Dias R, et al. Age-associated metabolic and epigenetic barriers during direct repro-gramming of mouse fibroblasts into induced cardiomyocytes[J]. Aging Cell, 2025, 24(2): e14371.

[32] [32] He X, Wang Q, Zhao Y, et al. Effect of intramyocardial grafting collagen scaffold with mesenchymal stromal cells in patients with chronic ischemic heart disease: a randomized clinical trial[J]. JAMA Netw Open, 2020, 3(9): e2016236.

[33] [33] Jebran AF, Seidler T, Tiburcy M, et al. Engineered heart muscle allografts for heart repair in primates and humans[J]. Nature, 2025, 639(8054): 503-511.